» Articles » PMID: 17497026

Thermolabile Methylenetetrahydrofolate Reductase C677T Polymorphism and Homocysteine Are Risk Factors for Coronary Artery Disease in Moroccan Population

Overview
Specialty Biology
Date 2007 May 15
PMID 17497026
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Increased plasma total homocysteine (tHcy) levels have been shown to be a risk factor for coronary artery disease (CAD). The common methylenetetrahydrofolate reductase C677T (MTHFR C677T) polymorphism has been reported to be a strong predictor of mild hyperhomocysteinaemia (HHcy). We assessed whether this mutation was associated with increased risk of CAD and plasma levels of tHcy. We also evaluated interactions between this polymorphism, mild elevated tHcy levels and conventional risk factors of CAD. Method. Using PCR-RFLP analysis, we studied the frequency of the C677T genotypes and its effect on CAD and on tHcy concentrations in 400 subjects without and with CAD angiographically confirmed. There were 210 subjects with CAD and 190 subjects without CAD. Results. The frequencies of the C677T genotypes were 53% (59.5% in controls versus 48.1% in cases), 34.8% (32.1 in controls versus 37.1 in cases), and 11.8% (8.4% in controls versus 14.8% in cases), respectively, for 677CC, 677CT, and 677TT. The genotype frequencies were significantly different between case and control groups (P < .05). The 677T allele enhances the risk of CAD associated to HHcy (P < .01). In multivariate analysis models, MTHFR C677T polymorphism effect on CAD was masked by other risk factors. HHcy was only and independently influenced by MTHFR polymorphism and smoking habits, and it is a strong predictor of CAD independently of conventional risk factors. Conclusion. Our data suggest that HHcy is strongly and independently associated to CAD risk increase; and MTHFR C677T polymorphism and smoking habits were the main predictors of tHcy levels. The CAD risk increase is mainly associated with mild HHcy in 677TT, whereas in 677CT and 677CC it is mainly associated with the conventional risk factors.

Citing Articles

Association of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of carotid atherosclerosis: a cross-sectional analysis of 730 Chinese Han adults in Chongqing.

Peng X, Zhou Y, Wu X, Wang X, Bai H, Li Y BMC Cardiovasc Disord. 2020; 20(1):222.

PMID: 32404177 PMC: 7222312. DOI: 10.1186/s12872-020-01505-1.


Analysis of genetic polymorphism of methylenetetrahydrofolate reductase in a large ethnic Hakka population in southern China.

Zhao P, Hou J, Wu H, Zhong M Medicine (Baltimore). 2018; 97(50):e13332.

PMID: 30557982 PMC: 6320045. DOI: 10.1097/MD.0000000000013332.


Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: a systematic review and updated meta-analysis.

Luo Z, Lu Z, Muhammad I, Chen Y, Chen Q, Zhang J Lipids Health Dis. 2018; 17(1):191.

PMID: 30115070 PMC: 6097444. DOI: 10.1186/s12944-018-0837-y.


Association of methylenetetrahydrofolate reductase gene (C677T) with the risk of hypertension in Morocco.

Nassereddine S, Kassogue Y, Korchi F, Habbal R, Nadifi S BMC Res Notes. 2015; 8:775.

PMID: 26654251 PMC: 4677044. DOI: 10.1186/s13104-015-1772-x.


Association of the APOE, MTHFR and ACE Genes Polymorphisms and Stroke in Zambian Patients.

Atadzhanov M, Mwaba M, Mukomena P, Lakhi S, Rayaprolu S, Ross O Neurol Int. 2014; 5(4):e20.

PMID: 24416484 PMC: 3883065. DOI: 10.4081/ni.2013.e20.


References
1.
Hegele R, Pollex R . Genetic and physiological insights into the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol. 2005; 289(3):R663-9. DOI: 10.1152/ajpregu.00275.2005. View

2.
Engbersen A, Franken D, Boers G, STEVENS E, Trijbels F, Blom H . Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995; 56(1):142-50. PMC: 1801334. View

3.
Ray J . Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998; 158(19):2101-6. DOI: 10.1001/archinte.158.19.2101. View

4.
Boushey C, Beresford S, Omenn G, Motulsky A . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274(13):1049-57. DOI: 10.1001/jama.1995.03530130055028. View

5.
Jacques P, Bostom A, Williams R, Ellison R, Eckfeldt J, Rosenberg I . Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93(1):7-9. DOI: 10.1161/01.cir.93.1.7. View